tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PTGX Stock Latest News

Protagonist Therapeutics’ PN-881 Study: A Closer Look at Market Implications
Company AnnouncementsProtagonist Therapeutics’ PN-881 Study: A Closer Look at Market Implications
3d ago
PTGX
Protagonist receives Breakthrough Therapy Designation for rusfertide
PremiumThe Fly
Protagonist receives Breakthrough Therapy Designation for rusfertide
17d ago
PTGX
Protagonist Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating
PremiumRatings
Protagonist Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating
1M ago
PTGX
Protagonist Therapeutics Completes Promising Phase 2 Study on PTG-300 for Polycythemia Vera
PremiumCompany Announcements
Protagonist Therapeutics Completes Promising Phase 2 Study on PTG-300 for Polycythemia Vera
1M ago
PTGX
Protagonist Therapeutics’ Rusfertide Study: A Promising Update for Polycythemia Vera Treatment
PremiumCompany Announcements
Protagonist Therapeutics’ Rusfertide Study: A Promising Update for Polycythemia Vera Treatment
1M ago
PTGX
Protagonist Therapeutics price target raised to $69 from $67 at Citizens JMP
PremiumThe FlyProtagonist Therapeutics price target raised to $69 from $67 at Citizens JMP
1M ago
PTGX
Protagonist Therapeutics: Promising Future with Strong Pipeline and Financial Stability
Premium
Ratings
Protagonist Therapeutics: Promising Future with Strong Pipeline and Financial Stability
1M ago
PTGX
Protagonist Therapeutics Reports Q2 2025 Results and Pipeline Progress
Premium
Company Announcements
Protagonist Therapeutics Reports Q2 2025 Results and Pipeline Progress
1M ago
PTGX
Protagonist Therapeutics: Promising Developments in Rusfertide and Icotrokinra Drive Buy Rating
PremiumRatings
Protagonist Therapeutics: Promising Developments in Rusfertide and Icotrokinra Drive Buy Rating
1M ago
PTGX
Protagonist Therapeutics files automatic mixed securities shelf
PremiumThe Fly
Protagonist Therapeutics files automatic mixed securities shelf
1M ago
PTGX
Protagonist Therapeutics reports Q2 EPS (55c), consensus (52c)
PremiumThe Fly
Protagonist Therapeutics reports Q2 EPS (55c), consensus (52c)
1M ago
PTGX
Protagonist Therapeutics’ Rusfertide Study: Long-term Safety in Focus
PremiumCompany Announcements
Protagonist Therapeutics’ Rusfertide Study: Long-term Safety in Focus
1M ago
PTGX
Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising NDA Submission and Market Potential of Icotrokinra
PremiumRatingsOptimistic Buy Rating for Protagonist Therapeutics Driven by Promising NDA Submission and Market Potential of Icotrokinra
2M ago
PTGX
Protagonist Therapeutics Positioned for Growth with Icotrokinra’s Strong FDA Approval Prospects and Strategic Partnerships
Premium
Ratings
Protagonist Therapeutics Positioned for Growth with Icotrokinra’s Strong FDA Approval Prospects and Strategic Partnerships
2M ago
PTGX
Protagonist Therapeutics, Johnson & Johnson submit icotrokinra NDA to FDA
Premium
The Fly
Protagonist Therapeutics, Johnson & Johnson submit icotrokinra NDA to FDA
2M ago
JNJ
PTGX
Protagonist announces NDA submission by Johnson & Johnson for icotrokinra
PremiumThe Fly
Protagonist announces NDA submission by Johnson & Johnson for icotrokinra
2M ago
JNJ
PTGX
Citizens JMP healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens JMP healthcare analysts hold an analyst/industry conference call
2M ago
ABVX
PTGX
Protagonist Therapeutics: Strategic Advancements and Promising Data Drive Buy Rating
PremiumRatings
Protagonist Therapeutics: Strategic Advancements and Promising Data Drive Buy Rating
2M ago
PTGX
Strategic Entry and Innovation: Protagonist Therapeutics’ Potential in the Obesity Market with PN-477
PremiumRatings
Strategic Entry and Innovation: Protagonist Therapeutics’ Potential in the Obesity Market with PN-477
2M ago
PTGX
Protagonist Therapeutics: Promising Developments in Obesity Treatment with PN-477 and Strategic Growth Opportunities
PremiumRatingsProtagonist Therapeutics: Promising Developments in Obesity Treatment with PN-477 and Strategic Growth Opportunities
2M ago
PTGX
Protagonist Therapeutics: Promising Obesity Program and Strategic Partnerships Drive Buy Rating
Premium
Ratings
Protagonist Therapeutics: Promising Obesity Program and Strategic Partnerships Drive Buy Rating
2M ago
PTGX
Protagonist Therapeutics’ Innovative Oral Obesity Candidate PN477 Earns Buy Rating from Analyst Geoff Meacham
Premium
Ratings
Protagonist Therapeutics’ Innovative Oral Obesity Candidate PN477 Earns Buy Rating from Analyst Geoff Meacham
2M ago
PTGX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >